Thanks KB!See Boffin’s post which is his conjecture that the results were for RC220 and then DT replied that there would be variance. Hence my follow-up questions. Obviously KB’s reference to DT’s previous post also supports the hypothesis of RC220 being used in preclinical work. If all this is correct, then per my post, this is a good validation for us SHs regarding RC220’s efficacy being similar to RC110. (AIMO!)
DT hasn’t refuted this yet… let’s wait and watch.
Ann: Bisantrene shows potent anticancer activity in AML models, page-35
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
